NECTIN4
ENSG00000143217
Target class
Adhesion
Chromosome
1
Approved drugs
1
Clinical candidates (approved and in development)
1
- Approved drugs
- 1
- Clinical candidates (approved and in development)
- 1
- Chemical probe available
- No
- Target name
- NECTIN4
- Gene name
- Nectin cell adhesion molecule 4
- Gene symbol
- NECTIN4
- Previous gene symbols
- PVRL4
- Protein name
- Nectin-4 (Ig superfamily receptor LNIR) (Nectin cell adhesion molecule 4) (Poliovirus receptor-related protein 4) [Cleaved into: Processed poliovirus receptor-related protein 4]
- nectin-4
- PRR4
- LNIR
- Gene biotype
- Protein coding
- Gene family
- V-set domain containing|C2-set domain containing|Nectins and nectin-like molecules
- Target class
- Adhesion
- Target type
- Human gene
- Tissues expressed in
- 17
- Protein localisation evidence grade
- Supported
- Highest tissue expression
- 205.24
- Tissue specificity (Gini)
- 0.9
- Tissue specificity (tau)
- 0.945
- KEGG gene identifiers
- hsa:81607
- Protein interaction confidence
- 0.923875
- Protein interaction partners
- 8
- R-HSA-418990
- R-HSA-420597
- End position
- 161090045
- Start position
- 161070988
- Chromosome
- 1
- Strand
- Reverse
- Cell membrane
- Single-pass type I membrane protein . Cell junction, adherens junction . Note=Colocalizes with AFDN at cadherin-based adherens junctions (PubMed:11544254).
- SUBCELLULAR LOCATION: [Processed poliovirus receptor-related protein 4]: Secreted . Note=The secreted form is found in breast tumor patients (PubMed:15784625).
- Plasma membrane
- PubMed 11544254
- PubMed 15784625
- Tissue specificity (tau)
- 0.944742
- Expression inequality (Gini)
- 0.900126
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)
- 205.24
- Skin - Not Sun Exposed (Suprapubic)
- 203.62
- Esophagus - Mucosa
- 148.56
- Vagina
- 120.83
- Minor Salivary Gland
- 52.05
Expression in transcripts per million
- Skin - Sun Exposed (Lower leg)205.24
- Skin - Not Sun Exposed (Suprapubic)203.62
- Esophagus - Mucosa148.56
- Vagina120.83
- Minor Salivary Gland52.05
- Prostate16.91
- Breast - Mammary Tissue16.74
- Bladder9.46
- Lung5.81
- Stomach4.96
- Kidney - Medulla4.05
- Kidney - Cortex2.76
- Pancreas2.69
- Fallopian Tube1.91
- Colon - Transverse1.69
- Testis1.68
- Pituitary1.25
- Small Intestine - Terminal Ileum0.93
- Cells - EBV-transformed lymphocytes0.5
- Thyroid0.44
- Cervix - Endocervix0.39
- Cells - Cultured fibroblasts0.39
- Cervix - Ectocervix0.31
- Adipose - Subcutaneous0.27
- Artery - Coronary0.22
And 29 more, listed on the interactive page.
Biological processes
- GO:0045953
- GO:0005576
- GO:0005886
- GO:0005912
- GO:0070062
- GO:0005515
- GO:0042802
- GO:0048018
Related records
Trials (75)
- A Clinical Study of Intismeran Autogene (V940) Treatment and Pembrolizumab in People With Bladder Cancer (V940-005/INTerpath-005)
- A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
- A Safety Study of Enfortumab Vedotin in Indian Adults With Urothelial Cancer
- A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
- A Study of Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Plus Enfortumab Vedotin (EV) With and Without Pembrolizumab in Advanced Urothelial Carcinoma (MK-3475-04C/KEYMAKER-U04)
- A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
- A Study of Enfortumab Vedotin for Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer
- A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
- A Study of Enfortumab Vedotin in People With Adenoid Cystic Carcinoma
- A Study of Enfortumab Vedotin in People With Urothelial Carcinoma of the Upper Urinary Tract
- A Study of Escalating Doses of ASG-22CE Given as Monotherapy in Subjects With Metastatic Urothelial Cancer and Other Malignant Solid Tumors That Express Nectin-4
- A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
- A Study of Intravesical Enfortumab Vedotin For Treatment of Patients With Non-muscle Invasive Bladder Cancer (NMIBC)
- A Study of the Safety and Pharmacokinetics of AGS-22M6E in Subjects With Malignant Solid Tumors That Express Nectin-4
- A Study to Evaluate Enfortumab Vedotin (ASG-22CE) in Chinese Participants With Locally Advanced or Metastatic Urothelial Cancer Who Previously Received Platinum-containing Chemotherapy and Programmed Cell Death Protein-1 ( PD 1) / (Programmed Death Ligand-1 (PD-L1) Inhibitor Therapy
- A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)
- A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelial Cancer (EV-301)
- A Study to Find Out if Enfortumab Vedotin Given With Pembrolizumab Helps People With Muscle-invasive Bladder Cancer Keep Their Bladder
- A Study to Survey Adults in South Korea With Cancer Who Receive PADCEV Injection
- An Expanded Access Treatment Protocol of Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma
Drugs (1)
- Enfortumab vedotin Nectin-4 binding agent